BLA 761391 · Galderma Labs Lp
Nemluvio
Nemolizumab-Ilto · Injection
NovelLast checked: Nov 20, 2026Latest source record: Jun 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 13, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
11 Phase 3, 6 recruiting
FAERS reports
15,930
1,068 serious, 156 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NEMLUVIO · NEMOLIZUMAB-ILTO 30mg · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nemolizumab" as an intervention, any sponsor and status, largest first.
- Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
Galderma R&DIndustry
NCT03989206 · 1,935 participants · Start Dec 30, 2019 · Primary completion Aug 31, 2026
Drug: Nemolizumab · For: Moderate-to-Severe Atopic Dermatitis
Sites: Birmingham, Alabama; Guntersville, Alabama; Scottsdale, Arizona · 343 sites in all
- Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Galderma R&DIndustry
NCT03985943 · 941 participants · Start Jun 27, 2019 · Primary completion Dec 29, 2021
Drug: Placebo; Nemolizumab · For: Moderate-to-Severe Atopic Dermatitis
Sites: North Little Rock, Arkansas; Cerritos, California; Fountain Valley, California · 174 sites in all
- Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic DermatitisPivotal-lookingCompleted
Galderma R&DIndustry
NCT03989349 · 787 participants · Start Jun 30, 2019 · Primary completion Feb 23, 2022
Drug: Placebo; Nemolizumab · For: Moderate-to-Severe Atopic Dermatitis
Sites: Birmingham, Alabama; Guntersville, Alabama; Scottsdale, Arizona · 138 sites in all
- A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Pivotal-lookingActive, not recruiting
Galderma R&DIndustry
NCT04204616 · 500 participants (planned) · Start Jan 11, 2021 · Primary completion Oct 26, 2026
Drug: Nemolizumab · For: Prurigo Nodularis
Sites: Birmingham, Alabama; Fountain Valley, California; Los Angeles, California · 164 sites in all
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Pivotal-lookingCompleted
Galderma R&DIndustry
NCT04501666 · 286 participants · Start Sep 11, 2020 · Primary completion Nov 11, 2022
Drug: Nemolizumab 30 mg; Placebo · For: Prurigo Nodularis
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 100 sites in all
- A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)Pivotal-lookingCompleted
Galderma R&DIndustry
NCT04501679 · 274 participants · Start Aug 11, 2020 · Primary completion Mar 30, 2022
Drug: Nemolizumab; Placebo · For: Prurigo Nodularis
Sites: Fountain Valley, California; San Diego, California; Washington D.C., District of Columbia · 74 sites in all
- A Phase 2 Study of CIM331 for Atopic Dermatitis PatientsPivotal-lookingCompleted
Chugai PharmaceuticalIndustry
NCT01986933 · 264 participants · Start Nov 2013 · Primary completion Apr 2015
Drug: nemolizumab (CIM331) · For: Atopic Dermatitis
Sites: Anniston, Alabama; San Diego, California; Miami, Florida · 18 sites in all
- To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe PruritusPivotal-lookingCompleted
Galderma R&DIndustry
NCT05075408 · 258 participants · Start Mar 18, 2022 · Primary completion Jan 4, 2024
Drug: Nemolizumab; Nemolizumab and 1 more · For: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Sites: Bakersfield, California; Glendale, California; La Palma, California · 64 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue5,792
- device malfunction2,529
- pruritus1,581
- inappropriate schedule of product administration1,578
- incorrect dose administered1,544
- rash1,056
- drug ineffective947
- device use error658
- dermatitis atopic556
- headache505
- eczema420
- device leakage403
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 2 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 161 |
| 2025 | 7,279 |
| 2026 | 8,478 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nemluvio (Nemolizumab-Ilto)
2024 spending
$13.7M
Beneficiaries
967
2,005 claims
Per beneficiary
$14,159
$4,193.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $13,691,381 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu AWL, Wong MM, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Network Meta-Analysis
- Focused update: Guidelines of care for the management of atopic dermatitis in adults.
Davis DMR, Frazer-Green L, Alikhan A, et al. · J Am Acad Dermatol 2025 · Systematic Review, Practice Guideline
- Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG, Yosipovitch G, Legat FJ, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence.
Shanshal M, Uthayakumar A · J Dermatolog Treat 2026 · Systematic Review
- Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
Silverberg JI, Wollenberg A, Reich A, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
Kabashima K, Matsumura T, Komazaki H, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.